Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) on August 4, 2016. The filing serves to announce the company's financial results for the first quarter ended June 30, 2016.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the detailed financial results are contained within the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached Exhibit 99.1 for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document notes that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific revenue and net income figures for the quarter ended June 30, 2016, by reviewing the full text of the press release (Exhibit 99.1).
- Confirm the company's cash position and liquidity status as detailed in the attached earnings release.
- Review the press release for any updated financial guidance or strategic outlook provided by management.
- Note that the financial data in this 8-K is furnished but not "filed" under Section 18 of the Exchange Act, limiting liability for the information contained therein.